Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, reported routine tax-related share dispositions. On March 9, 2026, a total of 1,399 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations on vesting restricted stock units granted in 2022 and 2023. After these withholdings, she directly holds 226,271 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported routine share dispositions tied to tax withholding rather than open-market sales. On March 9, 2026, a total of 1,619 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations from vesting restricted stock units granted on March 7, 2022 and March 6, 2023. After these transactions, Estepan directly owned 203,080 shares of Sarepta common stock.
Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a tax-related share disposition linked to restricted stock vesting. On March 2, 2026, 450 shares of common stock were withheld by the company at $16.20 per share to cover tax withholding obligations from restricted stock units granted on March 1, 2024. After this withholding transaction, Wong directly owned 135,595 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported equity award activity tied to prior grants. On March 1, 2026, 8,125 Performance Stock Units earned under a March 1, 2024 award were converted into 8,125 shares of common stock as they vested based on milestone achievement.
To cover tax withholding on the vesting of this PSU award and related restricted stock units, the company withheld a total of 4,176 shares of common stock on March 2, 2026, valued at $16.20 per share, as tax-withholding dispositions. After these non‑market transactions, Estepan directly owned 204,699 common shares.
Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity. On March 1, 2026, 8,125 Performance Stock Units previously earned under a March 1, 2024 PSU award vested and were converted into the same number of common shares, based on the compensation committee’s milestone achievement determination. On March 2, 2026, the company withheld 3,718 and 767 common shares, respectively, at $16.20 per share to cover tax withholding obligations related to the vesting of PSU and RSU awards, leaving Rodino-Klapac with 227,670 directly held common shares.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares. On February 26, 2026, he exercised options for 2,069 shares and 5,381 shares of common stock at an exercise price of $13.71 per share. These transactions increased his directly held common stock to 200,750 shares, according to the filing footnote, and involved no reported open-market sales.
Sarepta Therapeutics is a commercial-stage biopharma company focused on RNA-targeted drugs, siRNA therapies and gene therapies for rare neuromuscular diseases, led by Duchenne muscular dystrophy.
The company sells four approved Duchenne products—EXONDYS 51, VYONDYS 53, AMONDYS 45 and the gene therapy ELEVIDYS—and recorded $1,864.3 million in product net revenues for the year ended December 31, 2025, up from $1,788.0 million in 2024 and $1,144.9 million in 2023.
2025 brought significant challenges. Top-line results from the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 did not meet the primary endpoint, and Sarepta plans further FDA discussions on their approval status. ELEVIDYS was temporarily suspended in the U.S. after serious safety events, later resuming only for ambulatory patients and gaining a boxed warning for acute liver injury and acute liver failure while the non-ambulatory indication was removed from labeling.
The FDA also placed a clinical hold on Sarepta’s LGMD gene therapy trials after a patient death, with SRP‑9003’s path now contingent on additional sirolimus data. At the same time, Sarepta entered a large siRNA collaboration with Arrowhead, paying a $500.0 million upfront fee plus substantial milestones and royalties, and continues to partner with Roche on ELEVIDYS ex-U.S. and with Catalent and Aldevron for manufacturing.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported an equity compensation transaction involving performance stock units. He acquired 1,875 performance stock units on February 25, 2026 as a grant/award, bringing his directly held performance stock units to 8,125.
According to the disclosure, these 1,875 shares represent units earned under a performance stock unit award originally granted on March 1, 2024, based on the compensation committee’s determination of the company’s achievement of specified milestones. The earned units are scheduled to vest on March 1, 2026, if he continues to provide service to the company through that date.
Sarepta Therapeutics, Inc. reported that executive Louise Rodino-Klapac, President of R&D and Tech Ops, acquired 1,875 Performance Stock Units (PSUs) on the basis of a prior equity award. These PSUs were earned under a PSU grant originally awarded on March 1, 2024.
The number of PSUs earned reflects the compensation committee’s assessment of the company’s achievement of specified milestones in that award. Following this transaction, Rodino-Klapac holds a total of 8,125 PSUs. The earned PSUs are scheduled to vest on March 1, 2026, provided she continues to serve the company through that date.